Based on the outcomes of the CBYL719 × 2101 trial, alpelisib showed promising results and tolerable toxicity in PIK3CA-mutant tumor patients, demonstrating that isoform-selective PI3K inhibitors combined with other antitumor regimens may be efficient in treating PIK3CA-mutant tumors [155]. This evidence concerns the gene PIK3CA and neoplasm.